PHARMACEUTICAL DEVELOPMENT PROJECT CHECKLIST TEMPLATE Created by ChecklistGuro (https://checklistguro.com) --- TARGET IDENTIFICATION & VALIDATION --- [ ] Initial Disease Area Selection Rationale [ ] Disease Prevalence Data Source (WHO Data, CDC Data, Internal Market Research, Published Literature) [ ] Estimated Patient Population (Millions) [ ] Unmet Medical Need Assessment Summary [ ] Supporting Data Files (Market Research, Epidemiology) [ ] Target Validation Approach (Genetic Studies, Cellular Assays, Animal Models, Combination) [ ] Date of Target Validation Milestone Completion --- DRUG DISCOVERY --- [ ] Initial Target Hypothesis [ ] Target Validation Method (Genetic Studies, Cellular Assays, Animal Models, Literature Review) [ ] Number of Initial Hit Compounds [ ] Initial Screening Data Files [ ] Screening Technologies Used (High-Throughput Screening (HTS), Fragment-Based Screening, Virtual Screening, Affinity Chromatography) [ ] Date of Initial Hit Identification --- PRECLINICAL DEVELOPMENT --- [ ] Rationale for Preclinical Study Design [ ] In Vitro Assay Raw Data [ ] Maximum Tolerated Dose (MTD) [ ] Start Date of In Vivo Toxicology Study [ ] Animal Species Used in Toxicology Studies (Rat, Mouse, Dog, Other) [ ] Toxicology Endpoints Evaluated (Clinical Chemistry, Hematology, Histopathology, Body Weight, Food Consumption) [ ] Summary of Key Findings from Preclinical Studies --- FORMULATION DEVELOPMENT --- [ ] Target Dosage (mg) [ ] Dosage Form (Tablet, Capsule, Oral Solution, Injection, Other) [ ] Excipient Selection Rationale [ ] Preliminary Formulation Data (e.g., solubility, stability) [ ] Particle Size (µm) [ ] Polymorphic Form (Form I, Form II, Other) [ ] Formulation Optimization Completion Date --- CLINICAL TRIAL PLANNING (PHASE 1) --- [ ] Clinical Trial Protocol Summary [ ] Protocol Approval Date [ ] Planned Number of Participants [ ] Primary Endpoint Measurement (Pharmacokinetics (PK), Pharmacodynamics (PD), Safety & Tolerability) [ ] Key Inclusion Criteria (Age >= 18, Confirmed Diagnosis, Stable Medication Regimen, Adequate Organ Function) [ ] First Patient Enrollment Planned Date [ ] Investigator's Brochure (IB) Review & Updates --- CLINICAL TRIAL EXECUTION (PHASE 1) --- [ ] Patient Enrollment Start Date [ ] First Patient Dosing Date [ ] Number of Patients Enrolled [ ] Adverse Event Reporting Summary (Phase 1) [ ] Investigational Product Batch Number (Batch 1, Batch 2, Batch 3) [ ] Dosing Time (Example Patient) [ ] Patient Consent Form (Sample) --- CLINICAL TRIAL PLANNING (PHASE 2) --- [ ] Detailed Protocol Description [ ] Planned Patient Enrollment Number [ ] Planned Study Start Date [ ] Estimated Study End Date [ ] Primary Endpoint Measurement Method (Objective Measurement, Patient Reported Outcome, Clinical Assessment) [ ] Investigational Site Selection Criteria (Patient Population Availability, Investigator Experience, Equipment Capabilities, Regulatory Compliance) [ ] Statistical Analysis Plan Review Status (Not Started, In Progress, Completed) [ ] Statistical Analysis Plan Document --- CLINICAL TRIAL EXECUTION (PHASE 2) --- [ ] Patient Enrollment Start Date [ ] Patient Enrollment End Date [ ] Number of Patients Enrolled [ ] Summary of Adverse Events Reported [ ] Data Monitoring Committee (DMC) Review Status (Pending, Completed, Deferred) [ ] Data Quality Checks Completed? (Data Entry Verification, Source Data Verification, Query Resolution) [ ] Time of Critical Event (e.g., Serious Adverse Event) [ ] Clinical Study Report Draft --- CLINICAL TRIAL PLANNING (PHASE 3) --- [ ] Phase 3 Trial Protocol Summary [ ] Planned Number of Participants [ ] Primary Endpoint Measurement Method (Subjective Assessment, Objective Measurement, Biomarker Analysis) [ ] Planned First Patient Enrollment Date [ ] Estimated Trial Completion Date [ ] Key Inclusion Criteria (Age Range, Disease Stage, Prior Treatment History, Specific Biomarker Status) [ ] Statistical Analysis Plan (SAP) --- CLINICAL TRIAL EXECUTION (PHASE 3) --- [ ] Trial Start Date [ ] Number of Participants Enrolled [ ] Summary of Protocol Deviations (if any) [ ] Data Monitoring Committee (DMC) Review Status (Pending, Completed - No Concerns, Completed - Concerns Identified, Completed - Recommendation Made) [ ] Date of Last Safety Review [ ] Key Findings from Interim Analysis (if applicable) [ ] Interim Analysis Report (if applicable) [ ] Investigational Product Accountability Status (Complete and Accurate, Minor Discrepancies, Significant Discrepancies) --- REGULATORY SUBMISSION (NDA/MAA) --- [ ] Summary of Clinical Data [ ] Clinical Study Reports (CSRs) [ ] Patient Enrollment Numbers [ ] Submission Date [ ] Regulatory Agency (FDA, EMA, Other) [ ] Description of Manufacturing Process [ ] CMC Data --- MANUFACTURING PROCESS DEVELOPMENT & VALIDATION --- [ ] Process Flow Description [ ] Critical Process Parameter (CPP) - Temperature (Celsius) [ ] CPP - pH [ ] Equipment Validation Status (Not Started, In Progress, Completed, Failed) [ ] Process Validation Protocol Document [ ] Process Validation Start Date [ ] Process Validation Completion Date [ ] Critical Quality Attributes (CQA) Addressed (Purity, Potency, Dissolution, Moisture Content, Particle Size) --- POST-APPROVAL ACTIVITIES & PHASE 4 TRIALS --- [ ] Phase 4 Trial Start Date [ ] Summary of Post-Approval Safety Data [ ] Number of Adverse Events Reported [ ] Protocol Deviations Identified? (Yes, No) [ ] Supporting Documentation (e.g., Safety Reports) [ ] Summary of Risk Management Plan Updates [ ] Next Periodic Safety Update Report Due Date --- INTELLECTUAL PROPERTY MANAGEMENT --- [ ] Patent Application Number(s) [ ] Filing Date (Patent Application 1) [ ] Filing Date (Patent Application 2) [ ] Trademark Registration Number(s) [ ] Patent Status (Application 1) (Filed, Published, Pending, Granted, Abandoned, Expired) [ ] Number of Patent Claims [ ] Summary of IP Strategy [ ] Copies of Patent Documents --- PROJECT MANAGEMENT & REPORTING --- [ ] Project Budget (Total) [ ] Actual Spend to Date [ ] Project Start Date [ ] Projected Completion Date [ ] Project Status (Not Started, In Progress, On Hold, Completed, Cancelled) [ ] Key Risks & Mitigation Strategies [ ] Project Dashboard Report [ ] Reporting Frequency (Weekly, Bi-Weekly, Monthly) --- END OF TEMPLATE --- Transform this text into a digital, automated, and trackable mobile app! Visit: https://checklistguro.com/templates/project-management/pharmaceutical-development-project-checklist-template (Click "Install Template" to launch your digital inspection tool immediately)